2024 Wrap Up

What did you learn most at the 22nd Annual Discovery on Target this past September 30-October 3, 2024? Who did you most value meeting of the over 1,000 international attendees?

The drug discovery science across 220+ presentations included fresh coverage of covalent chemistries and induced proximity, synthetic biology, cancer antibodies, generative AI, and translational models, as well as favorites like kinases, immunomodulation, degraders, membrane proteins, GPCRs, and more.

Expanding beyond these specialties: Our Plenary Keynote speakers highlighted molecules with therapeutic impacts on obesity and cancer. The returning Diversity Discussion brought more candor and inspiration with a focus on mentorship. And the new Venture Capitalists Panel illuminated and provoked with its perspectives on driving innovation.

Search the agendas and speaker biographies for the “what” and “who” across 13 conference tracks, 4 symposia, 9 interactive courses, 2 in-depth training seminars, and breakout discussions for every track.

The technologies and services enabling this research – beyond agenda talks and the buzzing Exhibit Hall of 85 companies – got additional recognition from our new Best of Show Award honoring the year’s most impactful new products. (Congratulations again, Dalriada Drug Discovery!) Further enlivening the Hall: 110+ dynamic posters and a new book raffle/author signing with pharmacology and DELs experts.

For a review of presentations relevant to fragment-based drug design (including computational and covalent approaches) by Daniel A. Erlanson, PhD, Chief Innovation Officer, Innovation and Discovery, Frontier Medicines Corporation, see his Practical Fragments blogpost.

We hope your Discovery on Target experience was rewarding and advances your work long term. Feel free to share topic ideas and submit a speaker proposal for 2025. Less than a year before our 23rd Annual event next September 22-25 back in Boston!

Sincerely,
An-Dinh Nguyen
Team Lead, Discovery on Target
anguyen@healthtech.com